Education
About Us
Working with TipRanks
Follow Us
Mirum Pharmaceuticals Inc (MIRM)
NASDAQ:MIRM
MIRM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$23.14 - $54.23
Previous CloseN/A
Volume92.82K
Average Volume (3M)478.32K
Market Cap
$1.93B
Enterprise Value$2.03B
Total Cash (Recent Filing)$222.50M
Total Debt (Recent Filing)$317.76M
Price to Earnings (P/E)―
Beta0.63
Next Earnings
May 01, 2025EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.85
Shares Outstanding49,454,334
10 Day Avg. Volume512,583
30 Day Avg. Volume478,316
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.84
Price to Cash Flow (P/CF)-113.70
P/FCF Ratio0.00
Enterprise Value/Market Cap1.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit7.94
Enterprise Value/Ebitda-41.37
Forecast
1Y Price Target
$63.75Price Target Upside63.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Mirum Pharmaceuticals News
---
Bulls Say, Bears Say
Bulls Say
Drug Approval And ExpansionLivmarli becomes the first approved drug for cholestatic pruritus in patients with ALGS and PFIC.
Financial PerformanceStrong financial position (~$293M cash on hand); expect positive cash flow.
Revenue GrowthMIRM expects 2025 total revenue of $420M-$435M representing 27% Y/Y growth at the midpoint which is considered attainable.
Bears Say
Clinical TrialsTimelines for volixibat’s programs were reaffirmed, with enrollment completion for volixibat’s VISTAS trial in primary sclerosing cholangitis (PSC) expected in 2H25.
Market CompetitionLivmarli continues to grow at a steady clip with IBAT penetration at ~40% in Alagille syndrome and tailwinds from further penetration, new diagnoses, and increased revenue per patient.
---
Ownership Overview
9.27% Insiders
25.13% Mutual Funds
0.41% Other Institutional Investors
52.61% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MIRM FAQ
What was Mirum Pharmaceuticals Inc’s price range in the past 12 months?
Mirum Pharmaceuticals Inc lowest stock price was $23.14 and its highest was $54.23 in the past 12 months.
What is Mirum Pharmaceuticals Inc’s market cap?
Mirum Pharmaceuticals Inc’s market cap is $1.93B.
When is Mirum Pharmaceuticals Inc’s upcoming earnings report date?
Mirum Pharmaceuticals Inc’s upcoming earnings report date is May 01, 2025 which is in 9 days.
How were Mirum Pharmaceuticals Inc’s earnings last quarter?
Mirum Pharmaceuticals Inc released its earnings results on Feb 26, 2025. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.258 by -$0.232.
Is Mirum Pharmaceuticals Inc overvalued?
According to Wall Street analysts Mirum Pharmaceuticals Inc’s price is currently Undervalued.
Does Mirum Pharmaceuticals Inc pay dividends?
Mirum Pharmaceuticals Inc does not currently pay dividends.
What is Mirum Pharmaceuticals Inc’s EPS estimate?
Mirum Pharmaceuticals Inc’s EPS estimate is -0.33.
How many shares outstanding does Mirum Pharmaceuticals Inc have?
Mirum Pharmaceuticals Inc has 49,454,334 shares outstanding.
What happened to Mirum Pharmaceuticals Inc’s price movement after its last earnings report?
Mirum Pharmaceuticals Inc reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.258. Following the earnings report the stock price went down -7.007%.
Which hedge fund is a major shareholder of Mirum Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in MIRM
---
Mirum Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$63.75 (63.04% Upside)
$63.75 (63.04% Upside)
Blogger Sentiment
Bullish
MIRM Sentiment 71%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 73.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $962.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days <0.1%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
61.23%
12-Months-Change
Fundamentals
Return on Equity
-37.08%
Trailing 12-Months
Asset Growth
3.73%
Trailing 12-Months
Company Description
Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
---
MIRM Company Deck
---
MIRM Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Mirum Pharmaceuticals demonstrated significant financial growth and strong pipeline advancements, with notable achievements including the approval of CTEXLI and the expansion of LIVMARLI's market. However, high operating expenses and challenges in fully penetrating the Alagille syndrome market were noted. The positive aspects of financial performance and pipeline progress outweigh the challenges, indicating a strong outlook for the company.Read More>---
MIRM Stock 12 Month Forecast
Average Price Target
$63.75
▲(63.04% Upside)
Technical Analysis
Vericel
―
Beam Therapeutics
―
Kymera Therapeutics
―
MoonLake Immunotherapeutics
―
Edgewise Therapeutics
―
Best Analysts Covering MIRM
1 Year
1 Year Success Rate
28/35 ratings generated profit
1 Year Average Return
+28.57%
reiterated a buy rating 2 months ago
Copying Mani Foroohar's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +28.57% per trade.
---